Exclusive Summary

• Backed by highly prestigious US-FDA and UK-MHRA GMP certifications alongside current US registration, validating uncompromising quality and enabling accelerated market access globally.
• Offers a complete dosage range (10-80mg) addressing comprehensive clinical needs for moderate-to-high intensity lipid-lowering therapies as recommended by the AHA/ESC, while being a staple of the WHO Essential Medicines List.
• Targets the immense global cardiovascular disease burden leveraging China's resilient supply chain to deliver exceptional cost competitiveness, creating highly profitable commercial distribution opportunities via originator substitution.